Therapeutic effectiveness of thalidomide in a patient with treatment-resistant restless legs syndrome

Aaro V. Salminen, Nathalie Schandra, Barbara Schormair, Konrad Oexle, Juliane Winkelmann

Publikation: Beitrag in FachzeitschriftArtikelBegutachtung

2 Zitate (Scopus)

Abstract

Recent developments in the genetics of restless legs syndrome (RLS) revealed associations of disease risk with genetic loci containing the genes coding cereblon, the protein bound by thalidomide, and its endogenous substrate MEIS2, whose degradation is inhibited by the thalidomide-cereblon interaction. Therefore it was hypothesized that thalidomide may be a potential treatment option for RLS. Here we report on the therapeutic effect of thalidomide in a patient with otherwise treatment-resistant RLS who received 100 mg thalidomide off-label for 3 weeks. The female patient, severely affected by RLS before treatment, experienced significant amelioration of the symptoms, increased self-reported sleep quality, and better daytime functioning during thalidomide treatment. This therapeutic success warrants larger studies investigating the efficacy of drugs of the thalidomide class in RLS.

OriginalspracheEnglisch
Seiten (von - bis)1815-1817
Seitenumfang3
FachzeitschriftJournal of Clinical Sleep Medicine
Jahrgang6
Ausgabenummer10
DOIs
PublikationsstatusVeröffentlicht - 15 Okt. 2020
Extern publiziertJa

Fingerprint

Untersuchen Sie die Forschungsthemen von „Therapeutic effectiveness of thalidomide in a patient with treatment-resistant restless legs syndrome“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren